The proposed rules would align with the February 2026 ruling on physician dispensing in Publix Super Markets, Inc. v. Department of Financial Services.
The proposed rules would align with the February 2026 ruling on physician dispensing in Publix Super Markets, Inc. v. Department of Financial Services.
The hearing will take place on July 15th, allowing interested stakeholders to attend virtually.
As part of proposed updates to the Healthcare Service rules and the state fee schedule, additional changes are up for debate.
Targets for consideration include pharmacy rules, physical therapy, DME, and ancillary services.
A remote hearing will be held on May 28th, with comments accepted through June 5th. If enacted, changes will take effect July 1st.
The DWC will work with system participants to develop the audit plan, including timeframe, size, and case selection.
Discussions centered around evolving approaches to carrier compliance and oversight, reflecting an increasing shift toward data-driven system alignment.
Among many educational sessions, Sandy Shtab, Healthesystems VP of Industry and State Affairs, joined a panel on Medical Experience.
Senate Bill 1215 was discussed, and it appears unlikely the proposed reimbursement caps will be passed.
The committee issued new recommendations related to 300 mg ibuprofen, gabapentin and pregabalin, cyclobenzaprine, and tizanidine.
Matters discussed included physician dispensing, missed appointment fees, passive therapy utilization, and interpreter bill denials.
Stakeholders may send specific legislative recommendations to the DWC, if they are supported by data, and with relevant background or context.
The April 15th hybrid meeting will take place from 12:30 PM to 2:30 PM PST, covering a wide variety of pharmacy topics.
Two Oklahoma bills heading for House consideration would establish a NADAC based reimbursement floor, minimum dispensing fees, and a shortened 30 day payment timeframe.
While injured workers have an absolute choice over their pharmacist, physicians are not considered pharmacists and therefore not entitled to reimbursement.
